R. Bernabé Caro - Servicio de Oncología Médica. Hospital Universitario Virgen del Rocío. Sevilla

基本信息

浏览量：25

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 40 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

138P Faecalibacterium prausnitzii enhances tumor response to perioperative nivolumab and chemotherapy

A. Rodriguez-Festa, R. Serna-Blasco, E. Nadal, J.L. Gonzalez-Larriba, A. Martinez-Marti,R. Bernabe Caro, J. Bosch-Barrera, J. Casal Rubio,V. Calvo de Juan, M.A. Insa Molla,S. Ponce Aix,N. Reguart Aransay,

ESMO Open (2024)

引用0浏览0引用

OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

S.S. Ramalingam, T.-E. Ciuleanu,R. Bernabe Caro, M. Nishio, H. Mizutani, J.-S. Lee, C. Audigier-Valette, R. Sangha, L. Urban, J.A. Burgers, A. Pluzanski, K.H. Lee,

Journal of Thoracic Oncologyno. 11 (2023): S76-S77

引用0浏览0引用

1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain

E. Nadal,C. Alvarez Fernandez, H. Arasanz,S. Peralta Muñoz,M. Lázaro Quintela, C. Teixido,V. Calvo de Juan,R.M. Alvarez,J. Baena Espinar, J. Valdivia-Bautista, E. Arriola, R. Lastra,

Annals of Oncology (2023): S738-S739

引用0浏览0引用

1050P Sensitization to immunotherapy through manipulation of tumor transcription by lurbinectedin

J.S. Russo-Cabrera,S. Ponce Aix, P. Cozar, A. Luengo,A.F. Navarro Mendivil,R. Bernabe Caro,M.E. Olmedo Garcia,J.M. Trigo Perez, J. Zugazagoitia, L. Paz-Ares, I. Otano Andres

Annals of Oncology (2023): S636-S636

引用0浏览0引用

PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227

H. Borghaei, J.R. Brahmer,J.-S. Lee,T.-E. Ciuleanu,R. Bernabe Caro, M. Nishio, L. Urban, C. Audigier-Valette, L. Lupinacci, R. Sangha, L.G. Paz-Ares, M. Reck,

Journal of Thoracic Oncologyno. 3 (2023): e8-e9

引用0浏览0引用

First-Line Nivolumab plus Ipilimumab (NIVO plus IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227

H. Borghaei, J. R. Brahmer, J. -S. Lee, T. -E. Ciuleanu,R. Bernabe Caro, M. Nishio, L. Urban, C. Audigier-Valette, L. Lupinacci, R. Sangha, L. G. Paz-Ares, M. Reck,

JOURNAL OF THORACIC ONCOLOGYno. 3 (2023): E8-E9

引用0浏览0引用

Six-year Survival and HRQoL Outcomes with 1L Nivolumab plus Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

S. S. Ramalingam, T. -E. Ciuleanu,R. Bernabe Caro, M. Nishio, H. Mizutani,J. -S. Lee, C. Audigier-Valette, R. Sangha, L. Urban, J. A. Burgers, A. Pluzanski, K. H. Lee,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S76-S77

引用0浏览0引用

LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6

M.C. Garassino,J. Mazieres,M. Reck, C. Chouaid,H. Bischoff,N. Reinmuth, L.S. Cove-Smith, T. Mansy,D.L. Cortinovis, M.R. Migliorino,A. Delmonte,J. García Sanchez,

Annals of Oncology (2023): S1301-S1302

引用0浏览0引用

41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

H. Borghaei, D. Balli, L. Paz-Ares, M. Reck,S.S. Ramalingam, J.R. Brahmer,T-E. Ciuleanu, A. Pluzanski,J-S. Lee, J. Gainor, M. Schenker, A. Schoenfeld,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S64-S65

引用0浏览0引用

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

H. Borghaei,T.-E. Ciuleanu,J.-S. Lee,A. Pluzanski,R. Bernabe Caro,M. Gutierrez, Y. Ohe,M. Nishio, J. Goldman, N. Ready, D.R. Spigel,S.S. Ramalingam,

Ann Oncol（2023）

引用5浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn